The federal government just handed a massive gift to the MedTech lobby, and everyone is cheering like it’s a victory for patients. It isn't.
The Centers for Medicare & Medicaid Services (CMS) recently moved to accelerate the Transitional Coverage for Emerging Technologies (TCET) pathway. The logic is simple: get new gadgets to patients faster by cutting the red tape between FDA approval and insurance reimbursement. On paper, it sounds like a win-only scenario. In reality, we are watching the slow-motion erosion of clinical evidence in exchange for quarterly earnings reports.
I have watched dozens of startups burn through VC funding because they couldn't prove their device actually worked better than a $50 generic alternative. They hate the "valley of death"—that period between getting a 510(k) clearance and actually getting paid by Medicare. But that valley exists for a reason. It is the only thing left protecting the American taxpayer from paying premium prices for mediocre technology.
The Myth of the Innovation Gap
The industry narrative is that patients are dying while waiting for CMS to make a coverage decision. This is a manufactured crisis.
The FDA’s job is to ensure a device is safe and does what the manufacturer says it does. It does not ensure the device is "reasonable and necessary" for the Medicare population. If a company builds a robotic spine assistant that costs $200,000 but offers the same outcomes as a skilled surgeon with a manual kit, should the taxpayer foot the bill immediately?
By shrinking the window for evidence collection, TCET doesn't "speed up innovation." It subsidizes laziness. It allows companies to skip the rigorous, long-term outcomes studies that used to be the gold standard. We are trading "proven efficacy" for "market velocity."
The TCET Trap: Coverage with Evidence Development
The "compromise" offered by CMS is Coverage with Evidence Development (CED). This means Medicare pays for the device while the company collects data. It sounds fair. It is actually a disaster for scientific integrity.
Once a device is covered and the checks are flowing, the urgency to complete high-quality trials vanishes. I have seen companies treat CED as a permanent residency. They drag their feet on data collection because they know that once the "provisional" coverage is granted, pulling it back is a political nightmare. CMS rarely has the stomach to tell thousands of seniors that the device their doctor just started using is being de-funded because the data came back lukewarm.
Why 510(k) is the Real Enemy
To understand why "speeding up payments" is dangerous, you have to understand how these devices get to market. Most people assume every new medical device undergoes clinical trials. They don't.
The vast majority of medical devices are cleared through the 510(k) pathway. To pass, a company only has to prove their device is "substantially equivalent" to a "predicate device" already on the market.
- Company A has a hip implant from 1995.
- Company B makes a slight tweak and cites Company A as a predicate.
- Company C tweaks Company B’s version.
By the time we get to Company G, the "innovation" is a distant cousin of a thirty-year-old design, yet it’s marketed as a breakthrough. Now, CMS wants to pay for these "breakthroughs" faster. We are accelerating the reimbursement of clones.
The False Promise of Breakthrough Designation
The TCET pathway is specifically for "Breakthrough Devices." This label is the most successful branding exercise in the history of the Department of Health and Human Services.
Getting a Breakthrough Designation from the FDA does not mean the device is a cure for cancer. It means the device could provide for more effective treatment of life-threatening or irreversibly debilitating diseases. It is a statement of potential, not a statement of fact.
When CMS hitches its wagon to this designation, it is essentially gambling with public funds. We are paying top-tier prices for "potential" while the manufacturers offload the risk of failure onto the public. If the device fails to live up to the hype five years down the line, the company has already cashed the checks. The patients are the ones left with the hardware in their bodies.
Precision Medicine or Precise Marketing
We are told that faster payments are necessary for "precision medicine"—AI-driven diagnostics and complex implants. But look at the data. A study published in JAMA analyzed devices that received the Breakthrough Designation. A staggering number of them were cleared based on "surrogate endpoints" rather than actual clinical outcomes.
A surrogate endpoint is a marker—like a lab result—that is supposed to correlate with clinical benefit. It is not the benefit itself. We are paying for devices that move a needle on a dashboard without proof that the patient actually lives longer or feels better.
The Cost of the "Early Access" Obsession
Every dollar Medicare spends on an unproven "breakthrough" is a dollar taken away from services we know work. The opportunity cost is staggering.
The industry argues that early payment allows them to reinvest in R&D. That is a boardroom fantasy. Early payment allows them to reinvest in sales reps and marketing blitzes to capture market share before the long-term data catches up to them. It turns the Medicare trust fund into a venture capital pool, but without the equity upside for the taxpayer.
The Dangerous Incentive Structure
When you speed up payments, you change the behavior of the entire ecosystem:
- Venture Capitalists stop funding companies that aim for "Total Evidence." They fund companies that can hit the TCET milestones the fastest.
- Engineers focus on "iterative novelty" rather than "disruptive utility."
- Hospitals become showrooms for unproven tech because the reimbursement is guaranteed, regardless of whether the patient actually benefits more than they would from the "old" way.
We are building a healthcare system that prizes the "New" over the "Better."
What We Should Be Doing Instead
If we actually wanted to fix the system, we wouldn't be talking about speed. We would be talking about Value-Based Safe Harbors.
Instead of blanket coverage for any device with a "Breakthrough" sticker, Medicare should implement a sliding scale of reimbursement tied to validated outcomes.
- Stage 1: Initial clearance gets you base-level reimbursement (cost of production + small margin).
- Stage 2: As you prove 1-year efficacy, your reimbursement rate increases.
- Stage 3: If you prove superior long-term outcomes compared to the standard of care, you get the premium "Innovation" rate.
This puts the risk back on the manufacturer. It forces companies to be certain their device works before they ask for the keys to the treasury.
The Reality of Professional Liability
Critics will say this approach stifles progress. I’ve heard the lobbyists' scripts. They say, "You're keeping life-saving tech from patients."
Let’s be honest: most "innovations" in the MedTech space are incremental at best. A slightly more ergonomic handle on a catheter is not life-saving; it's a convenience. A software update to an imaging suite that uses a slightly different algorithm is not a revolution; it's a patch.
When we treat every iteration as a "breakthrough" that deserves instant, high-speed payment, we dilute the meaning of the word. We create a noisy, crowded marketplace where the truly revolutionary tools—the ones that actually change the trajectory of human health—get lost in the shuffle of "fast-tracked" mediocrity.
The Uncomfortable Truth
The push for TCET isn't about the patient. It’s about the exit strategy.
For a MedTech startup, the goal is rarely to be a standalone company for thirty years. The goal is to get bought by Medtronic, Stryker, or Johnson & Johnson. The biggest hurdle to an acquisition is the "reimbursement risk." If a startup can point to a guaranteed, fast-tracked CMS payment pathway, their valuation doubles overnight.
We are altering federal policy to inflate the M&A valuations of medical startups. We are using the Medicare budget to de-risk the portfolios of private equity firms.
If a device is truly a breakthrough, it will survive the scrutiny of a rigorous coverage process. If it can't survive the wait, it probably wasn't that much of a breakthrough to begin with. Stop asking how we can pay faster. Start asking why we are so eager to pay for things we aren't even sure work.
Stop subsidizing the "Beta Test" of American healthcare.
